[Percutaneous ablation of pulmonary tumours: state-of-the-art 2004].
Percutaneous radiofrequency ablation (RFA) and laser-induced interstitial thermotherapy (LITT) are well established since many years in liver and other soft tissue tumors. During the past 2 years there are increasing reports on applications in pulmonary tumors. There are, however, numerous differences to ablations in other organs: indications in pulmonary metastases and lung cancer have to be balanced against the specific possibilities of well-established surgical resections. Tissue specific features require different concepts of energy deployment and complications and methods for assessment of therapeutic effectiveness vary from other applications. Other aspects, however, are quite clear, yet. There are specific established indications particularly for thermoablation of pulmonary metastases. Tumor ablation is easily performed by experienced interventional radiologists and serious complications are rare. Patient acceptance is good. Further studies are required on indications, technical requirements, therapy control and particularly long-term results.
Diederich
S
S
Institut für Diagnostische und Interventionelle Radiologie/Nuklearmedizin, Marienhospital Düsseldorf. s.diederich@marien-hospital.de
Hosten
N
N
D002283:Carcinoma, Bronchogenic / Q000601:surgery*; D017115:Catheter Ablation; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D053685:Laser Therapy; D008168:Lung / Q000473:pathology / Q000601:surgery; D008175:Lung Neoplasms / Q000556:secondary* / Q000601:surgery*; D019060:Minimally Invasive Surgical Procedures; D010043:Outcome and Process Assessment, Health Care; D010166:Palliative Care